Lipocine Inc.
LPCN Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.44
KIRA · Stoqly’s AI analyst, in plain words
- Lipocine Inc. had $2.0M of revenue in fiscal 2025, down 82.3% on the year before.
- Its operating margin was −524.7%, down 514.4 pts: of every 100 in sales, about −525 is left after running the business.
- Lipocine Inc. lost $9.6M in fiscal 2025.
Market cap
$11.8M
P/E
—
Revenue
$2.0M
Net income
−$9.6M
Free cash flow
—
Operating margin
−524.7%
Lipocine Inc. in 30 seconds · fiscal 2025
Are sales growing?
−82.3%
No. Sales fell 82.3% last year.
Does it make a profit?
−487.0%
No. It lost money last year.
How healthy are the accounts?
0 / 7
Weak. It passes 0 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Lipocine Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- Lipocine Inc.
- CIK
- 0001535955
Lipocine Inc. · LPCN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $16.1M | $0.5M | −$2.9M | $11.2M | $2.0M |
| Revenue growth | — | −96.9% | −670.2% | — | −82.3% |
| Operating margin | 19.5% | −2,423.9% | 629.0% | −10.3% | −524.7% |
| Net income | −$0.6M | −$10.8M | −$16.4M | $0.0M | −$9.6M |
| Net margin | −3.9% | −2,151.7% | 573.6% | 0.1% | −487.0% |
| Diluted EPS | −$0.01 | −$2.15 | −$3.14 | — | −$1.69 |
| Cash | |||||
| Cash from operations | −$4.4M | −$12.0M | −$11.9M | −$1.2M | −$9.8M |
| Capital expenditure | $0.0M | $0.1M | $0.0M | $0.1M | — |
| Free cash flow | −$4.4M | −$12.1M | −$11.9M | −$1.3M | — |
| FCF margin | −27.4% | −2,420.5% | 416.7% | −11.7% | — |
| Share count change | 57.3% | −94.0% | 0.3% | 2.9% | 5.3% |
| Debt and strength | |||||
| Cash and short-term investments | $44.6M | $32.5M | $22.0M | $21.6M | $14.9M |
| Debt incl. finance leases | $4.0M | — | — | — | — |
| Shareholders' equity | $45.6M | $35.6M | $20.4M | $21.0M | $14.5M |
| Net debt / EBITDA | −12.9x | — | — | — | — |
| Current ratio | 8.3x | 20.3x | 8.7x | 14.8x | 6.7x |
| Interest coverage | 15.5x | −447.2x | — | — | — |
| Returns and quality | |||||
| Return on capital | 50.4% | — | — | — | — |
| Return on equity | −2.1% | −26.5% | −58.4% | 0.0% | −54.3% |
| Return on tangible equity | −1.4% | −30.2% | −80.3% | 0.0% | −66.5% |
| Piotroski F-score | 4 | 2 | 1 | 4 | 0 |
| Altman Z'' | 1.7 | 7.2 | −19.7 | −8.6 | −32.7 |
Insiders bought, 12 months
$0.5M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lipocine Inc. · LPCN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.44 a share, the company is worth $11.8M.
Source: SEC EDGAR XBRL filings (CIK 0001535955). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.